PLK1 and nonpapillary renal cell carcinoma: Targeting the addiction to Plk1 appears relevant to increase the sensitivity to chemotherapy14,15, which is consistent with volasertib-dependent ccRCC cell death in sunitinib-sensitive and sunitinib-resistant cells.